Rezultati pretraživanja
  1. prije 7 sati
    Odgovor korisniku/ci

    often compared to as competitor whose lunch it is stealing

    1 reply
  2. prije 10 sati

    Myriad Genetics Rating Lowered to Buy at BidaskClub

  3. prije 18 sati

    Zacks: Analysts Expect Myriad Genetics, Inc. Will Announce Quarterly Sales of $209.24 Million

  4. 2. velj

    Although the technical rating is only medium, does present a nice setup opportunity.

  5. 2. velj
    Odgovor korisniku/ci

    Given the reliance on the FDA for consumer safety implied within this article you should look at and the fact that the FDA demanded they alter their tests...

  6. 1. velj

    Myriad Genetics, Inc. Expected to Post Earnings of $0.31 Per Share

  7. 1. velj

    a bit volatility -2.90 % change recently

  8. 30. sij

    Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020

  9. 29. sij

    LeJeune Puetz Investment Counsel Sells 6,000 Shares of Myriad Genetics

  10. 29. sij

    Myriad up 6% premarket on FDA nod for test as Lynparza companion diagnostic

  11. 29. sij

    Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod

  12. 28. sij

    🚨🚨🚨 Thread 1/n others Here is my interpretation of the newly issued NCD from CMS. The source document is here:

    5 replies 5 proslijeđenih tweetova 19 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  13. 27. sij

    Phase 3 A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy…NCT02655016. Estimated Primary Completion Date - 02/2020

  14. 22. sij

    Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer. Learn more:

    3 proslijeđena tweeta 7 korisnika označava da im se sviđa
  15. 16. sij

    This the administrator for the Center for Medicare and Medicaid Services (CMS). This is what I referenced earlier with regard to and .

    “Just having price transparency is not enough. You need to have price AND quality information. When people look at just pricing they do not always pick the best provider, because they may think there is something wrong with the low cost option.”
    4 proslijeđena tweeta 25 korisnika označava da im se sviđa
  16. 12. sij

    1). It appears will MISS guidance for 2019 "preliminary... Actual results may differ." 2019 Guidance •Revenue: $220M •Samples: 500k 2019 Preliminary •Revenue: $216M •Samples: 482k Also lowering 2020 "aspirational" guidance of $500M

    4 proslijeđena tweeta 14 korisnika označava da im se sviđa
  17. 30. pro 2019.

    👀Watch:

    3 proslijeđena tweeta 34 korisnika označavaju da im se sviđa
  18. 30. pro 2019.

    It's make it happen Monday and here's what I may be trading IF we get an A+ Setup:

    3 proslijeđena tweeta 7 korisnika označava da im se sviđa
  19. 20. pro 2019.

    This is really erratic behavior by IR chief, threatening a breast cancer awareness non-profit? WTF?

    11 proslijeđenih tweetova 15 korisnika označava da im se sviđa
  20. 20. pro 2019.

    Not a great look coverage on

    1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.